Viruses as adjuvants for autoimmunity: Evidence from Coxsackievirus-induced myocarditis

Reviews in Medical Virology

Volumn 15, Issue 1, 2005, Pages 17-27

  Fairweather, DeLisa ^a   Frisancho Kiss, Sylvia ^a   Rose, Noel R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYOSIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; COXSACKIE VIRUS; COXSACKIE VIRUS B3; CYTOKINE RELEASE; DENDRITIC CELL; INFLAMMATORY INFILTRATE; MACROPHAGE; MAST CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; RECEPTOR UPREGULATION; REVIEW; T LYMPHOCYTE; VIRUS MYOCARDITIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNITY; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; HUMANS; IMMUNITY, NATURAL; MAST CELLS; MICE; MYOCARDITIS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 4;

EID: 11244310637     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.445     Document Type: Review

References (64)

1. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54: 1-13.
2. O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003; 2: 727-735.
3. Fairweather D, Kaya Z, Shellam GR, Lawson (James) CM, Rose NR. From infection to autoimmunity. J Autoimmun 2001; 16: 175-186.
4. Rose NR, Afanasyeva M. From infection to autoimmunity: the adjuvant effect. ASM News 2003; 3: 132-137.
5. Mackay IR, Toh B-H. Autoimmune hepatitis: the way we were, the way we are today and the way we hope to be. Autoimmunity 2002; 35: 293-305.
6. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001; 7: 899-905.
7. Esquivel PS, Rose NR, Kong YC. Induction of autoimmunity in good and poor responder mice with mouse thyroglobulin and lipopolysaccharide. J Exp Med 1977; 145: 1250-1263.
8. Lane JR, Neumann DA, LaFond-Walker A, Herskowitz A, Rose NR. LPS promotes CB3-induced myocarditis in resistant B10. A mice. Cell Immunol 1991; 136: 219-233.
9. Lenzo JC, Fairweather D, Shellam GR, Lawson (James) CM. Immunomodulation of murine cytomegalovirus-induced myocarditis in mice treated with lipopolysaccharide and tumor necrosis factor. Cell Immunol 2001; 213: 52-61.
10. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589: 1-13.
11. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
12. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-787.
13. Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc Natl Acad Sci USA 2000; 97: 13766-13771.
14. Underhill DM. Toll-like receptors: networking for success. Eur J Immunol 2003; 33: 1767-1775.
15. Yip HC, Karulin AY, Tary-Lehmann M, et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 1999; 162: 3942-3949.
16. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002; 196: 1645-1651.
17. Andrada JA, Rose NR, Kite JH Jr. Experimental thyroiditis in the rhesus monkey. IV. The role of thyroglobulin and cellular antigens. Clin Exp Immunol 1968; 3: 133-151.
18. Regner M, Lambert P-H. Autoimmunity through infection or immunization? Nat Immunol 2001; 2: 185-188.
19. Wucherpfennig KW. Structural basis of molecular mimicry. J Autoimmun 2001; 16: 293-302.
20. Fairweather D, Lawson CM, Chapman AJ, et al. Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin. Immunology 1998; 94: 263-270.
21. Lawson CM. Evidence for mimicry by viral antigens in animal models of autoimmune disease including myocarditis. Cell Mol Life Sci 2000; 57: 552-560.
22. Olson JK, Croxford JL, Calenoff MA, Dal Canto MC, Miller SD. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest 2001; 108: 311-318.
23. Rose NR, Mackay IR. Molecular mimicry: a critical look at exemplary instances in human diseases. Cell Mol Life Sci 2000; 57: 542-551.
24. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001; 2: 797-801.
25. Rose NR. Viral damage or 'molecular mimicry' - placing the blame in myocarditis. Nat Med 2000; 6: 631-632.
26. Neu N, Craig SW, Rose NR, Alvarez F, Beisel KW. Coxsackievirus-induced myocarditis in mice: cardiac myosin autoantibodies do not cross-react with the virus. Clin Exp Immunol 1987; 69: 566-574.
27. Mason D. A very high level of crossreactivity is an essential feature of the T cell receptor. Immunol Today 1998; 19: 395-404.
28. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-1950.
29. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by Coxsackievirus: initiation by bystander damage and not molecular mimicry. Nat Med 1998; 4: 781-785.
30. Rouse BT, Deshpande S. Viruses and autoimmunity: an affair but not a marriage contract. Rev Med Virol 2002; 12: 107-113.
31. Fairweather D, Rose NR. Type I diabetes: virus infection or autoimmune disease? Nat Immunol 2002; 3: 338-340.
32. Lowenstein CJ, Hill SL, Lafond-Walker A, et al. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 1996; 97: 1837-1843.
33. Hill SL, Rose NR. The transition from viral to autoimmune myocarditis. Autoimmunity 2001; 34: 169-176.
34. Huber SA, Gauntt CJ, Sakkinen P. Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv Virus Res 1998; 51: 35-80.
35. Horwitz MS, La Cava A, Fine C, Rodriguez E, Ilic A, Sarvetnick N. Pancreatic expression of interferon-γ protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis. Nat Med 2000; 6: 693-697.
36. Fong IW. New insights and updates for established entities. In Infections and the Cardiovascular System: New Perspectives, Fong IW (ed.). Kluwer Academic/Plenum Publishers: New York, 2003; 3-31.
37. Schoen FJ. The heart. In Robbins Pathologic Basis of Disease, Cotran RS, Kumar V, Collins T (eds). WB Saunders Co: Philadelphia, 1999; 544-599.
38. Gauntt CJ, Trousdale MD, LaBadie DR, Paque RE, Nealon T. Properties of Coxsackievirus B3 variants which are amyocarditic or myocarditic for mice. J Med Virol 1979; 3: 207-220.
39. Fairweather D, Yusung S, Frisancho (-Kiss) S, et al. IL-12Rβ1 and TLR4 increase IL-1β and IL-18-associated myocarditis and Coxsackievirus replication. J Immunol 2003; 170: 4731-4737.
40. Lenzo JC, Fairweather D, Cull V, Shellam GR, Lawson CM. Characterisation of murine cytomegalovirus myocarditis: cellular infiltration of the heart and virus persistence. J Mol Cell Cardiol 2002; 34: 629-640.
41. Fairweather D, Afanasyeva M, Rose NR. Cellular immunity: a role for cytokines. In Handbook of Systemic Autoimmune Diseases, Vol I, Doria A, Pauletto P (eds). Elsevier: Amsterdam, 2004; 3-17.
42. Pummerer C, Berger P, Fruhwirth M, Ofner C, Neu N. Cellular infiltrate, major histocompatiblity antigen expression and immunopathogenic mechanisms in cardiac myosin-induced myocarditis. Lab Invest 1991; 65: 538-547.
43. Wang Y, Afanasyeva M, Hill SL, Rose NR. Characterization of murine autoimmune myocarditis induced by self and foreign cardiac myosin. Autoimmunity 1999; 31: 151-162.
44. Afanasyeva M, Wang Y, Kaya Z, et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001; 159: 193-203.
45. Fairweather D, Frisancho-Kiss S, Gatewood S, et al. Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following Coxsackievirus B3 infection. Autoimmunity 2004; 37: 131-145.
46. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin Immunol 1998; 10: 383-390.
47. Kehoe KE, Brown MA, Imani F. Double-stranded RNA regulates IL-4 expression. J Immunol 2001; 167: 2496-2501.
48. Afanasyeva M, Wang Y, Kaya Z, et al. Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-7-independent pathway. Circulation 2001; 104: 3145-3151.
49. Cunningham MW. Cardiac myosin and the Th1/Th2 paradigm in autoimmune myocarditis. Am J Pathol 2001; 159: 5-12.
50. Gor DO, Rose NR, Greenspan NS. Th1-Th2: a Procrustean paradigm. Nat Immunol 2003; 4: 503-505.
51. Huber SA, Polgar J, Schultheiss P, Schwimmbeck P. Augmentation of pathogenesis of Coxsackievirus infections in mice by exogenous administration of interleukin-1 and interleukin-2. J Virol 1994; 68: 195-206.
52. Neumann DA, Lane JR, Alien GS, Herskowitz A, Rose NR. Viral myocarditis leading to cardiomyopathy: do cytokines contribute to pathogenesis? Clin Immunol Immunopathol 1993; 68: 181-190.
53. Smith SC, Allen PM. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res 1992; 70: 856-863.
54. Lane JR, Neumann DA, LaFond-Walker A, Herskowitz A, Rose NR. Interleukin 1 or tumor necrosis factor can promote Coxsackievirus B3-induced myocarditis in resistant B10A mice. J Exp Med 1992; 175: 1123-1129.
55. Feldman M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364-371.
56. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003; 111: S486-S494.
57. Secor VH, Secor WE, Gutekunst C-A, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000; 191: 813-821.
58. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297: 1689-1692.
59. Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000; 164: 5998-6004.
60. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol 2001; 167: 2250-2256.
61. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398-401.
62. Sundstrom JB, Little DM, Villinger F, Ellis JE, Ansari AA. Signaling through Toll-like receptors triggers HIV-1 replication in latently infected mast cells. J Immunol 2004; 172: 4391-4401.
63. Abel B, Thieblemont N, Quesniaux VJ, et al. Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol 2002; 169: 3155-3162.
64. Reiling N, Holscher C, Fehrenbach A, et al. Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol 2002; 169: 3480-3484.